首页 > 市场调查报告书 > 医疗设备

体外诊断癌症

欧洲肺癌筛检市场预测至 2030 年 - 区域分析 - 按癌症类型、技术、年龄层（50 岁及以上和 50 岁以下）和最终用户（医院、诊断中心等）

市场调查报告书

商品编码

1402526

欧洲肺癌筛检市场预测至 2030 年 - 区域分析 - 按癌症类型、技术、年龄层（50 岁及以上和 50 岁以下）和最终用户（医院、诊断中心等）

Europe Lung Cancer Screening Market Forecast to 2030 - Regional Analysis - by Cancer Type, Technology, Age Group (50 & Older and Below 50), and End User (Hospitals, Diagnostic Centers, and Others)

出版日期: 2023年11月01日 | 出版商:

The Insight Partners | 英文 131 Pages | 订单完成后即时交付

价格

简介目录图表

欧洲肺癌筛检市场预计将从2022年的5.9325亿美元成长到2030年的10.9099亿美元。预计2022年至2030年CAGR为7.9%。

肺癌发生率上升推动了欧洲肺癌筛检市场。

肺癌是全世界死亡的主要原因之一。肺癌筛检是癌症预防方法的重要组成部分。肺癌患者的预后在早期诊断时会更好，因此肺癌高风险族群应进行常规检查，以发现肺部癌性生长的形成。

根据癌症杂誌《肿瘤学年鑑》进行的研究，预计 2023 年欧盟地区将有约 1,261,990 名癌症患者死亡。肺癌死亡率将增加 1% 以上，达到每 10 万人 13.6 人。由于越来越多的英国女性比欧盟女性更早开始吸烟，英国女性肺癌死亡率将下降 13.8%，儘管每 10 万人中 16.2 人的死亡率仍高于欧盟女性。在英国，目前每 10 万人中肺癌患者的死亡人数高于乳癌（每 10 万人中 13.5 人）。

当研究人员特别检查了英国以外的五个欧盟国家的肺癌死亡率时，他们发现，虽然人口最多的六个国家（法国、德国、义大利、波兰和西班牙）的男性肺癌死亡率预计会下降，但他们发现，法国、义大利和西班牙的女性将分别增加约 14%、5.6% 和 5%。研究人员发现，在不同年龄层的女性中，25岁至64岁之间的肺癌预期死亡率有所下降，但65岁至75岁以上的女性肺癌预期死亡率上升，导致整体上升。此外，根据美国国家生物技术资讯中心 (NCBI) 的数据，义大利每年约有 41,000 例新诊断肺癌和 34,000 例死亡。因此，全球肺癌发生率的上升推动了肺癌筛检计画的启动，这反过来又推动了市场的成长。

欧洲肺癌筛检市场概况

欧洲肺癌筛检市场分为德国、英国、法国、义大利、西班牙和欧洲其他地区。该地区的增长归因于多种因素，例如肺癌发病率的增加以及人们对侧肺癌筛检和诊断的认识。此外，政府对筛检的支持不断增加，导致市场进一步成长。

肺癌盛行率的不断增加使得筛检对于早期发现变得极为重要。建议长期吸烟且没有任何肺癌相关症状的老年人进行肺癌筛检。医生使用低剂量电脑断层扫描 (LDCT) 扫描或 X 光进行筛检。

根据《胸腔肿瘤学杂誌》2022年6月发表的题为《德国肺癌》的文章，癌症是德国第二大常见死因之一，占所有死亡的25%。在男性中，肺癌排名第二位，仅次于心血管疾病，占全因死亡率的 6.5%。肺癌的年龄标化发生率男性和女性分别为52.1和32.7（每10万人），在男性中排名第二，在女性中排名第三（分别占所有新诊断癌症的13.3%和9.4%）。癌症诊断的平均年龄为70岁（男性）和69岁（女性）； 52% 的患者处于 IV 期。由于吸烟习惯的长期变化，自 20 世纪 90 年代以来，女性和男性的发病率趋同。目前，德国有四分之一的男性 (27.0%) 和五分之一的女性 (20.8%) 经常吸烟

欧洲肺癌筛检市场收入及 2030 年预测（百万美元）

欧洲肺癌筛检市场细分

欧洲肺癌筛检市场按癌症类型、技术、年龄层、最终用户和国家细分。

根据癌症类型，欧洲肺癌筛检市场分为非小细胞肺癌（NSCLC）和小细胞肺癌。 2022 年，非小细胞肺癌 (NSCLC) 细分市场在欧洲肺癌筛检市场中占据更大份额。

根据技术，欧洲肺癌筛检市场分为胸部X光检查、低剂量电脑断层扫描（LDCT）、液体切片等。 2022 年，低剂量电脑断层扫描 (LDCT) 领域在欧洲肺癌筛检市场中占据最大份额。

根据年龄组，欧洲肺癌筛检市场分为50岁及以上及50岁以下。2022年，50岁及以上细分市场在欧洲肺癌筛检市场中占有较大份额。

根据最终用户，欧洲肺癌筛检市场分为医院、诊断中心等。 2022年，医院细分市场在欧洲肺癌筛检市场中占据最大份额。

根据国家/地区，欧洲肺癌筛检市场分为德国、英国、法国、义大利、西班牙和欧洲其他地区。 2022年，德国在欧洲肺癌筛检市场占据主导地位。

西门子股份公司、荷兰皇家飞利浦公司、佳能公司、美敦力公司、GE HealthCare、Nuance Communications Inc 和 Intelerad Medical Systems 是欧洲肺癌筛检市场上的一些领先公司。

Lung cancer is among one of the main causes of mortality across the world. Lung cancer screening is a critical component of cancer prevention approaches. The prognosis of lung cancer patients is better when the disease is diagnosed early, so people at high risk of lung cancer are prompted to undergo routine checkups to detect the formation of cancerous growth in their lungs.

As per research conducted by the cancer journal Annals of Oncology, around 1,261,990 cancer patients are expected to die in 2023 in the EU region. Lung cancer death rates would increase by over 1% to 13.6 per 100,000. As more UK women started smoking earlier than those in the EU, there will be a 13.8% decrease in the death rate from lung cancer among women in the UK, although the death rate of 16.2 per 100,000 is still higher than among women in the EU. In the UK, lung cancer currently claims more per 100,000 than breast cancer, which claims 13.5 per 100,000.

When the researchers particularly examined lung cancer death rates in five EU nations in addition to the UK, they discovered that while rates are expected to decline for men in the most populous six nations (France, Germany, Italy, Poland, and Spain), they will increase for women in France, Italy, and Spain by about 14%, 5.6%, and 5%, respectively. The researchers discovered that among women in various age groups, expected mortality rates from lung cancer decreased among those between the ages of 25 and 64 but increased among those between the ages of 65 and over 75, leading to an increase overall. Also, according to the National Center for Biotechnology Information (NCBI), each year, ~41,000 new diagnoses of lung cancers and 34,000 deaths are recorded in Italy. Thus, the rising incidence of lung cancer worldwide is contributing to the initiation of lung cancer screening programs, which is, in turn, driving the market growth.

Europe Lung Cancer Screening Market Overview

The Europe lung cancer screening market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The regional growth is attributed to various factors, such as the increasing incidence of lung cancer and awareness of side lung cancer screening and diagnosis among people. Also, rising government support for screening has led to the further growth of the market.

The increasing prevalence of lung cancer has made its screening extremely important for early detection. Lung cancer screening is suggested for older adults who are long-time smokers and do not have any symptoms related to lung cancer. Physicians use a low-dose computerized tomography (LDCT) scan or X-ray for screening.

According to an article titled "Lung Cancer in Germany," published in the Journal of Thoracic Oncology, in June 2022, cancer is among the second most frequent cause of death in Germany, accounting for 25% of all deaths. In men, lung cancer ranks second after cardiovascular disease, accounting for 6.5% of all-cause mortality. With an age-standardized incidence rate of 52.1 and 32.7 and (per 100,000) in men and women, respectively, lung cancer ranks second in men and third in women (accounting for 13.3% and 9.4% of all newly diagnosed cancers, respectively). The average age of cancer diagnosis is 70 years (men) and 69 years (women); 52% of all patients present with stage IV. The incidence rates in women and men have converged since the 1990s because of long-term changes in smoking habits. Currently, every fourth man (27.0%) and every fifth woman (20.8%) in Germany smokes regularly

Europe Lung Cancer Screening Market Revenue and Forecast to 2030 (US$ Million)

Europe Lung Cancer Screening Market Segmentation

The Europe lung cancer screening market is segmented into cancer type, technology, age group, end user, and country.

Based on cancer type, the Europe lung cancer screening market is segmented into non-small cell lung cancer (NSCLC), and small cell lung cancer. The non-small cell lung cancer (NSCLC) segment held a larger share of the Europe lung cancer screening market in 2022.

Based on technology, the Europe lung cancer screening market is segmented into chest X-ray, low dose computed tomography (LDCT), liquid biopsy, and others. Low dose computed tomography (LDCT) segment held the largest share of the Europe lung cancer screening market in 2022.

Based on age group, the Europe lung cancer screening market is segmented into 50 and older, and below 50. 50 and older segment held the larger share of the Europe lung cancer screening market in 2022.

Based on end user, the Europe lung cancer screening market is segmented into hospital, diagnostic centre, and others. Hospital segment held the largest share of the Europe lung cancer screening market in 2022.

Based on country, the Europe lung cancer screening market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe lung cancer screening market in 2022.

Siemens AG, Koninklijke Philips NV, Canon Inc, Medtronic, GE HealthCare, Nuance Communications Inc, and Intelerad Medical Systems are some of the leading companies operating in the Europe lung cancer screening market.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe Lung Cancer Screening Market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in Europe Lung Cancer Screening Market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth Europe Market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

1. Introduction

1.1 Study Scope
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
- 1.3.1 Europe Lung Cancer Screening Market - by Technology
- 1.3.2 Europe Lung Cancer Screening Market - by Cancer Type
- 1.3.3 Europe Lung Cancer Screening Market - by Age Group
- 1.3.4 Europe Lung Cancer Screening Market - by End User
- 1.3.5 Europe Lung Cancer Screening Market - by Country

2. Europe Lung Cancer Screening Market - Key Takeaways

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Europe Lung Cancer Screening Market - Market Landscape

4.1 Overview
4.2 Europe PEST Analysis
4.3 Expert's Opinion

5. Europe Lung Cancer Screening Market - Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Rising Lung Cancer Incidences
5.2 Market Restraints
- 5.2.1 High Cost of Lung Cancer Screening Tests
5.3 Market Opportunities
- 5.3.1 Structured Lung Cancer Screening Program
5.4 Future Trends
- 5.4.1 Mobile Lung Cancer Screening Truck
5.5 Impact Analysis

6. Europe Lung Cancer Screening Market - Europe Analysis

6.1 Europe Lung Cancer Screening Market Revenue Forecast and Analysis

7. Europe Lung Cancer Screening Market - Revenue and Forecast to 2028 - By Cancer Type

7.1 Overview
7.2 Europe Lung Cancer Screening Market Revenue Share, by Cancer Type 2022 & 2030 (%)
7.3 Non-Small Cell Lung Cancer (NSCLC)
- 7.3.1 Overview
- 7.3.2 Non-Small Cell Lung Cancer (NSCLC): Europe Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Mn)
7.4 Small Cell Lung Cancer
- 7.4.1 Overview
- 7.4.2 Small Cell Lung Cancer: Europe Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe Lung Cancer Screening Market Analysis - by Technology

8.1 Overview
8.2 Low-Dose Computed Tomography (LDCT)
- 8.2.1 Overview
- 8.2.2 Low-Dose Computed Tomography (LDCT): Europe Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)
8.3 Chest X-ray
- 8.3.1 Overview
- 8.3.2 Chest X-ray: Europe Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)
8.4 Liquid Biopsy
- 8.4.1 Overview
- 8.4.2 Liquid Biopsy: Europe Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)
8.5 Others
- 8.5.1 Overview
- 8.5.2 Others: Europe Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)

9. Europe Lung Cancer Screening Market Analysis - by Age Group

9.1 Overview
9.2 & Older
- 9.2.1 Overview
- 9.2.2 & Older: Australia Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)
9.3 Below 50
- 9.3.1 Overview
- 9.3.2 Below 50: Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)

10. Europe Lung Cancer Screening Market Analysis - by End User

10.1 Overview
10.2 Hospitals
- 10.2.1 Overview
- 10.2.2 Hospitals: Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)
10.3 Diagnostic Centers
- 10.3.1 Overview
- 10.3.2 Diagnostic Centers: Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)
10.4 Others
- 10.4.1 Overview
- 10.4.2 Others: Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)

11. Europe Lung Cancer Screening Market - Revenue and Forecast to 2028 - Country Analysis

11.1 Europe: Europe Lung Cancer Screening Market Overview

12. Europe Lung Cancer Screening Market-Industry Landscape

12.1 Recent Growth Strategies
- 12.1.1 Overview

13. Company Profiles

13.1 Intelerad Medical Systems
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Nuance Communications Inc
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 GE HealthCare
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Medtronic
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Canon Inc.
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Koninklijke Philips NV
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Siemens AG
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments

14. Appendix

14.1 About The Insight Partners
14.2 Glossary of Terms

简介目录图表

List Of Tables

List of Tables

Table 1. Germany Europe Lung Cancer Screening Market, by Cancer Type - Revenue and Forecast to 20228 (US$ Million)
Table 2. Germany Europe Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
Table 3. Germany Europe Lung Cancer Screening Market, by Age Group - Revenue and Forecast to 2030 (US$ Million)
Table 4. Germany Europe Lung Cancer Screening Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 5. UK Europe Lung Cancer Screening Market, by Cancer Type - Revenue and Forecast to 20228 (US$ Million)
Table 6. UK Europe Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
Table 7. UK Europe Lung Cancer Screening Market, by Age Group - Revenue and Forecast to 2030 (US$ Million)
Table 8. UK Europe Lung Cancer Screening Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 9. France Europe Lung Cancer Screening Market, by Cancer Type - Revenue and Forecast to 20228 (US$ Million)
Table 10. France Europe Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
Table 11. France Europe Lung Cancer Screening Market, by Age Group - Revenue and Forecast to 2030 (US$ Million)
Table 12. France Europe Lung Cancer Screening Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 13. Italy Europe Lung Cancer Screening Market, by Cancer Type - Revenue and Forecast to 20228 (US$ Million)
Table 14. Italy Europe Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
Table 15. Italy Europe Lung Cancer Screening Market, by Age Group - Revenue and Forecast to 2030 (US$ Million)
Table 16. Italy Europe Lung Cancer Screening Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 17. Spain Europe Lung Cancer Screening Market, by Cancer Type - Revenue and Forecast to 20228 (US$ Million)
Table 18. Spain Europe Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
Table 19. Spain Europe Lung Cancer Screening Market, by Age Group - Revenue and Forecast to 2030 (US$ Million)
Table 20. Spain Europe Lung Cancer Screening Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 21. Rest of Europe Lung Cancer Screening Market, by Cancer Type - Revenue and Forecast to 20228 (US$ Million)
Table 22. Rest of Europe Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
Table 23. Rest of Europe Lung Cancer Screening Market, by Age Group - Revenue and Forecast to 2030 (US$ Million)
Table 24. Rest of Europe Lung Cancer Screening Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 25. Recent Growth Strategies in the Europe Lung Cancer Screening Market
Table 26. Glossary of Terms

List Of Figures

List of Figures

Figure 1. Europe Lung Cancer Screening Market Segmentation
Figure 2. Europe Lung Cancer Screening Market, by Country
Figure 3. Europe Lung Cancer Screening Market Overview
Figure 4. Non-Small Cell Lung Cancer Segment Held Largest Share of Cancer Type Segment in Europe Lung Cancer Screening Market
Figure 5. Asia Pacific Expected to Show Remarkable Growth During Forecast Period
Figure 6. Europe: PEST Analysis
Figure 7. Experts' Opinion
Figure 8. Europe Lung Cancer Screening Market Impact Analysis of Driver and Restraints
Figure 9. Europe Lung Cancer Screening Market - Revenue Forecast and Analysis - 2020-2030
Figure 10. Europe Lung Cancer Screening Market Revenue Share, by Cancer Type 2022 & 2030 (%)
Figure 11. Non-Small Cell Lung Cancer (NSCLC): Europe Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Small Cell Lung Cancer: Europe Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Europe Lung Cancer Screening Market, by Technology, 2022 & 2030 (%)
Figure 14. Low-Dose Computed Tomography (LDCT): Europe Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)
Figure 15. Chest X-ray: Europe Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)
Figure 16. Liquid Biopsy: Europe Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)
Figure 17. Others: Europe Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)
Figure 18. Europe Lung Cancer Screening Market, by Age group, 2022 & 2030 (%)
Figure 19. & Older: Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)
Figure 20. Below 50: Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)
Figure 21. Europe Lung Cancer Screening Market, by End User, 2022 & 2030 (%)
Figure 22. Hospitals: Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)
Figure 23. Diagnostic Centers: Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)
Figure 24. Others: Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)
Figure 25. Europe Lung Cancer Screening Market, by Key Country - Revenue (2022) (US$ Million)
Figure 26. Europe Lung Cancer Screening Market Revenue Share, by Country, (2022 & 2030)
Figure 27. Germany: Europe Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
Figure 28. UK: Europe Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
Figure 29. France: Europe Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
Figure 30. Italy: Europe Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
Figure 31. Spain: Europe Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
Figure 32. Rest of Europe: Europe Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)